BRD4 and acute myeloid leukemia: As a result, suppression of BRD4 with shRNA or JQ1, a bromodomain inhibitor, caused anti-leukemic effects in vitro and in vivo. An increasing number of studies show promising results of BET protein inhibition with preclinical inhibitors, such as JQ1 in AML cell lines, ex vivo patient samples, or mouse models (16, 17).